Monoclonal Antibody to EGFR (Epidermal Growth Factor Receptor)(Clone : 31G7)
|Amount :||100 µg|
|Isotype :||Mouse IgG2a Kappa|
|Purification :||Affinity Chromatography|
|Content :||100 µg in 500 µl PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic.|
|Storage condition :||Store the antibody at 4°C; stable for 6 months. For long-term storage; store at -20°C. Avoid repeated freeze and thaw cycles.|
This MAb recognizes a protein of 170kDa, identified as EGFR. EGFR is type I receptor tyrosine kinase with sequence homology to erbB-1, -2, -3 -4 or HER-1, -2, -3 -4. It binds to Epidermal Growth Factor (EGF), Transforming Growth Factor-a (TGF-a), Heparin-binding EGF (HB-EGF), amphiregulin, beta cellulin and epiregulin. EGFR is overexpressed in tumors of breast, brain, bladder, lung, gastric, head & neck, esophagus, cervix, vulva, ovary, and endometrium. It is predominantly present in squamous cell carcinomas.
Flow Cytometry (0.5-1µg/million cells in 0.1ml); Immunofluorescence (1-2µg/ml); Immunohistology (Formalin-fixed) (2-4µg/ml for 30 minutes at RT); (Digest formalin-fixed tissues with Protease at 1mg/ml PBS, pH 7.4 for 10 min at 37C); Optimal dilution for a specific application should be determined.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
1. Matsumoto Y, Kobayashi M, Shingu K, et al. An anaplastic pleomorphic xanthoastrocytoma with periventricular extension: An autopsy case report and review of the literature [published online ahead of print, 2020 Jun 23]. Neuropathology. 2020;10.1111/neup.12666. doi:10.1111/neup.12666
|Post transnational modification:||Methylated. Methylation at Arg-1199 by PRMT5 stimulates phosphorylation at Tyr-1197.|
|Tissue Specificity:||Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.|
|BioGrid:||108276. 1217 interactions.|